---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-109976"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:49:09.922160+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics to cut 45% of workforce; CLO Mike Ouimette departs

## Summary
- Reduction impacts ~45% of current employees; expected to substantially complete by end of Q2 2025.
- Total severance and related benefits estimated at $3.6M, primarily one-time cash termination benefits.
- Mike Ouimette, Chief Legal and Compliance Officer and Corporate Secretary, terminated effective May 1, 2025.

## SEC filing metadata
- accession: 0001193125-25-109976
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/d949809d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-109976
- JSON: https://secwatch.observer/filing/0001193125-25-109976.json
- Plain text: https://secwatch.observer/filing/0001193125-25-109976.txt

## Key facts
- Executive change
  Mike Ouimette was terminated as Chief Legal and Compliance Officer and Corporate Secretary at PLIANT THERAPEUTICS, INC..
  - Action: terminated
  - Role: Chief Legal and Compliance Officer and Corporate Secretary
  source text: On May 1, 2025, the Company announced that in connection with the workforce reduction, the employment of Mike Ouimette, the Company’s Chief Legal and Compliance Officer and Corporate Secretary, would terminate effective May 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm
- Restructurings & Charges
  PLIANT THERAPEUTICS, INC. announced a restructuring with charges of $3.6 million (approximately 45% of its current employees).
  - Type: restructuring
  - Charge: $3.6 million
  - Headcount: approximately 45% of its current employees
  source text: current employees. The Company expects to substantially complete the workforce reduction by the end of the second quarter of 2025. The Company expects to recognize approximately $3.6 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.